|
UCB Group - SWOT AnalysisPublished by: Datamonitor Published: Jun. 4, 2008 - 30 Pages Table of Contents
AbstractDatamonitor's UCB Group - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.UCB is a global biopharmaceutical company. The company focuses on severe diseases in the fields of central nervous system (including epilepsy), inflammation (including allergy), and oncology. It has more than 140 subsidiaries in Europe, North and South America, and Asia. The company is headquartered in Brussels, Belgium and employs more than 12,100 people. The company recorded revenues of E3,626 million (approximately $5,340.6 million) during the fiscal year ended December 2007, an increase of 42.1% over 2006. The operating profit of the company was E344 million (approximately $506.7 million) during fiscal year 2007, a decrease of 39.8% over 2006. The net profit was E161 million (approximately $237.1 million) in fiscal year 2007, a decrease of 56.1% over 2006. Scope of the Report
Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||